Two months after giving birth to their daughter, Jayla, Shelly Balboa and her partner, Joseph, noticed the left side of their ...
Investor's Business Daily on MSN1d
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A WeekNeurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome ...
Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...
Failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...
Keith Tapper CFA, an analyst from BMO Capital, maintained the Buy rating on Neurogene (NGNE – Research Report). The associated price target ...
Talks with the FDA haven’t gone according to plan. Seeking a streamlined pathway, Neurogene submitted a Regenerative Medicine ...
Coleen Rooney's little sister Rosie died when she was just 14 and the I'm A Celeb star, who tried to stay strong for her ...
Neurogene (NGNE) announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of ...
In an update posted today, Neurogene said that the "emerging treatment-related serious adverse event (SAE)" was a case of systemic hyperinflammatory syndrome, a rare and life-threatening immune ...
Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...
Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback